Home › Trials › NCT07318558

Sac-TMT maintenance for people with non-HRD advanced ovarian cancer

A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)

Phase 3 Interventional Merck Sharp & Dohme LLC · NCT07318558

This trial sees if sacituzumab tirumotecan (sac‑TMT), given with or without bevacizumab, can keep cancer from getting worse after surgery and first‑line platinum chemotherapy in people with non‑HRD advanced ovarian cancer.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment900 (estimated)
Ages18 Years and up
SexFemale
SponsorMerck Sharp & Dohme LLC Industry-sponsored
Drugs / interventionschemotherapy, Bevacizumab, sacituzumab
Locations41 sites (Miami Beach, Florida and 40 other locations)
Trial IDNCT07318558 on ClinicalTrials.gov

What this trial studies

This phase 3 trial enrolls people with epithelial ovarian, primary peritoneal, or fallopian tube carcinoma who have completed primary or interval debulking surgery and first‑line platinum‑based chemotherapy with at least stable disease. Eligible participants provide tumor tissue and are assigned to receive sac‑TMT maintenance with or without bevacizumab or to standard care (bevacizumab maintenance or observation) per protocol. The main outcome is how long participants live without their cancer getting worse (progression‑free survival), along with safety monitoring. The trial is sponsored by Merck and is conducted at multiple U.S. cancer centers.

Who should consider this trial

Good fit: Ideal candidates are adults with histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma who are non‑HRD positive, have completed primary or interval debulking surgery and first‑line platinum chemotherapy with at least stable disease, and can provide tumor tissue and attend participating U.S. sites.

Not a fit: People with nonepithelial tumors, certain low‑grade histologies (for example low‑grade serous or low‑grade endometrioid tumors), those who have not completed standard surgery or first‑line platinum chemotherapy, or who meet other exclusion criteria are unlikely to be eligible or benefit.

Why it matters

Potential benefit: If successful, this approach could extend the time without disease progression and offer a new maintenance option for people with non‑HRD advanced ovarian cancer.

How similar studies have performed: Antibody–drug conjugates and bevacizumab have shown activity in ovarian and other cancers, but sac‑TMT as maintenance specifically for non‑HRD advanced ovarian cancer is a newer approach without established phase 3 results to date.

Eligibility criteria

Show full inclusion / exclusion criteria 
The main inclusion criteria include but are not limited to the following:

* Has histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma of certain histologies.
* Has completed primary debulking surgery or interval debulking surgery.
* Has completed first-line (1L) platinum-based chemotherapy, with a response of stable disease, partial response, complete response or no evidence of disease per protocol.
* Has provided tumor tissue that is not previously irradiated.
* If human immunodeficiency virus (HIV) infected, has well-controlled HIV on antiretroviral therapy.
* Has undetectable hepatitis B virus (HBV) viral load and received HBV antiviral therapy if hepatitis B surface antigen (HBsAg)-positive.
* Has undetectable hepatitis C virus (HCV) viral load if has a history of HCV infection.

The main exclusion criteria include but are not limited to the following:

* Has nonepithelial cancers, low-grade serous tumors, low-grade endometrioid tumors, borderline tumors. mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor, and undifferentiated carcinoma.
* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
* Has a history of severe eye disease.
* Has active inflammatory bowel disease requiring immunosuppressive medication or a previous history of inflammatory bowel disease.
* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.
* Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD), which required steroids, or has current pneumonitis/ILD.
* Received prior systemic anticancer therapy, with the exception of the first-line platinum-based chemotherapy required by the inclusion criteria.
* Had a live or live-attenuated vaccine within 30 days of randomization.
* Has a known additional malignancy that is progressing or required active treatment within the past 3 years.
* Has active infection requiring systemic therapy.
* Has concurrent and active HBV and HCV infections.
* Has HIV infection and a history of Kaposi's sarcoma and/or multicentric Castleman's disease.
* Has not recovered from major surgery or has ongoing surgical complications.
* Has a homologous recombination deficiency (HRD)-positive, unknown, or inconclusive tumor status as determined by the central laboratory.
* Has active or ongoing stomatitis of any grade.

Where this trial is running

Miami Beach, Florida and 40 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Ovarian NeoplasmsOvarian Cancer
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.